κ-opioid receptor/dynorphin system: Genetic and pharmacotherapeutic implications for addiction

Trends in Neurosciences

Volumn 35, Issue 10, 2012, Pages 587-596

  Butelman, Eduardo R ^a   Yuferov, Vadim ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

opioid receptor; Addiction; Cocaine; Dynorphin; Heroin; Prescription opioids

Indexed keywords

DYNORPHIN; KAPPA OPIATE RECEPTOR;

COCAINE DEPENDENCE; COMORBIDITY; DNA MODIFICATION; EPIGENETICS; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HEREDITY; HEROIN DEPENDENCE; HUMAN; INDEL MUTATION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAPTATION, BIOLOGICAL; ANIMALS; BEHAVIOR, ADDICTIVE; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DYNORPHINS; ENKEPHALINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NARCOTIC ANTAGONISTS; POLYMORPHISM, GENETIC; PROTEIN PRECURSORS; RECEPTORS, OPIOID, KAPPA; RECURRENCE; STREET DRUGS;

EID: 84866770393     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.05.005     Document Type: Review

References (107)

1. Goldstein A., et al. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:6666-6670.
2. Mansour A., et al. Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. Mol. Cell. Neurosci. 1994, 5:124-144.
3. Simonin F., et al. Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7006-7010.
4. 35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 1997, 282:676-684.
5. Yuferov V., et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004, 14:793-804.
6. Horikawa S., et al. Isolation and structural organization of the human preproenkephalin B gene. Nature 1983, 306:611-614.
7. Mansour A., et al. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 1995, 700:89-98.
8. Pfeiffer A., et al. Psychotomimesis mediated by kappa opiate receptors. Science 1986, 233:774-776.
9. Roth B.L., et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11934-11939.
10. Carlezon W.A., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 2006, 316:440-447.
11. Zhang Y., et al. Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology 2004, 173:146-152.
12. Zhang Y., et al. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl.) 2005, 179:551-558.
13. Shirayama Y., et al. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J. Neurochem. 2004, 90:1258-1268.
14. Zhang H., et al. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur. J. Pharmacol. 2007, 570:89-96.
15. Chartoff E., et al. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012, 62:167-176.
16. Regier D.A., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
17. Kranzler H.R., et al. Validity of the SCID in substance abuse patients. Addiction 1996, 91:859-868.
18. Mason B.J., et al. Psychiatric comorbidity in methadone maintained patients. J. Addict. Dis. 1998, 17:75-89.
19. Daunais J.B., et al. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 1993, 4:543-546.
20. Spangler R., et al. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res. Mol. Brain Res. 1993, 19:323-327.
21. Unterwald E.M., et al. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 1994, 5:1613-1616.
22. Tjon G.H., et al. Delayed occurrence of enhanced striatal preprodynorphin gene expression in behaviorally sensitized rats: differential long-term effects of intermittent and chronic morphine administration. Neuroscience 1997, 76:167-176.
23. Wang X.M., et al. Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res. Mol. Brain Res. 1999, 66:184-187.
24. Bruchas M.R., et al. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010, 1314:44-55.
25. Wee S., Koob G.F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl.) 2010, 210:121-135.
26. Tejeda H.A., et al. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell. Mol. Life. Sci. 2012, 69:857-896.
27. Ahmed S.H., Koob G.F. Transition from moderate to excessive drug intake: change in hedonic set point. Science 1998, 282:298-300.
28. Mantsch J.R., et al. Predictable individual differences in the initiation of cocaine self-administration by rats under extended-access conditions are dose-dependent. Psychopharmacology (Berl.) 2001, 157:31-39.
29. Pickens C.L., et al. Neurobiology of the incubation of drug craving. Trends Neurosci. 2011, 34:411-420.
30. Kreek M.J. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. N. Y. Acad. Sci. 2000, 909:186-216.
31. Kakko J., et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361:662-668.
32. Dunn K.E., et al. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend. 2011, 119:1-9.
33. D'Souza M.S., Markou A. Neural substrates of psychostimulant withdrawal-induced anhedonia. Curr. Top. Behav. Neurosci. 2010, 3:119-178.
34. Han M.H., et al. Role of cAMP response element-binding protein in the rat locus ceruleus: regulation of neuronal activity and opiate withdrawal behaviors. J. Neurosci. 2006, 26:4624-4629.
35. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 1988, 244:1067-1080.
36. Spanagel R., et al. Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimic dopamine release. Psychopharmacology 1994, 115:121-127.
37. Unterwald E.M., et al. Chronic cocaine alters brain mu opioid receptors. Brain Res. 1992, 584:314-318.
38. Spangler R., et al. Regulation of kappa opioid receptor mRNA in the rat brain by 'binge' pattern cocaine administration and correlation with preprodynorphin mRNA. Brain Res. Mol. Brain Res. 1996, 38:71-76.
39. Tsukada H., et al. Effects of binge pattern cocaine administration on dopamine D1 and D2 receptors in the rat brain: an in vivo study using positron emission tomography. J. Neurosci. 1996, 16:7670-7677.
40. Zubieta J.K., et al. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat. Med. 1996, 2:1225-1229.
41. Unterwald E.M., et al. The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res. 2001, 900:103-109.
42. Volkow N.D., et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 2002, 46:79-82.
43. 11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol. Psychiatry 2004, 55:255-262.
44. Remmers A.E., et al. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J. Pharmacol. Exp. Ther. 1999, 288:827-833.
45. Spanagel R., et al. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2046-2050.
46. Zhang Y., et al. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl.) 2004, 172:422-429.
47. Chefer V.I., et al. Quantitative no-net-flux microdialysis permits detection of increases and decreases in dopamine uptake in mouse nucleus accumbens. J. Neurosci. Methods 2006, 155:187-193.
48. Doyon W.M., et al. κ-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration. Neuropharmacology 2006, 51:487-496.
49. Lindholm S., et al. Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens. Physiol. Behav. 2007, 92:167-171.
50. Beardsley P.M., et al. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl.) 2005, 183:118-126.
51. Carey A.N., et al. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. Eur. J. Pharmacol. 2007, 569:84-89.
52. Land B.B., et al. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 2008, 28:407-414.
53. Fagergren P., et al. Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. Eur. J. Neurosci. 2003, 17:2212-2218.
54. Everitt B.J., et al. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos. Trans. R. Soc. Lond. B: Biol. Sci 2008, 363:3125-3135.
55. Piras A.P., et al. Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area. Neuroscience 2010, 169:751-757.
56. Knoll A.T., et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol. Psychiatry 2011, 70:425-433.
57. Kreek M.J., et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat. Neurosci. 2005, 8:1450-1457.
58. Kreek M.J., et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev. 2005, 57:1-26.
59. Rouault M., et al. Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict. Biol. 2011, 16:334-346.
60. Dahl J.P., et al. Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005, 139B:106-108.
61. Williams T.J., et al. Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict. Biol. 2007, 12:496-502.
62. Nomura A., et al. Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci. Lett. 2006, 400:158-162.
63. Xuei X., et al. Association of the kappa-opioid system with alcohol dependence. Mol. Psychiatry 2006, 11:1016-1024.
64. Taqi M.M., et al. Prodynorphin promoter SNP associated with alcohol dependence forms noncanonical AP-1 binding site that may influence gene expression in human brain. Brain Res. 2011, 1385:18-25.
65. Clarke T.K., et al. An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population. Addict. Biol. 2009, 14:366-370.
66. Yuferov V., et al. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology 2009, 34:1185-1197.
67. Zimprich A., et al. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. 2000, 74:472-477.
68. Babbitt C.C., et al. Multiple functional variants in cis modulate PDYN expression. Mol. Biol. Evol. 2010, 27:465-479.
69. Zhang Y., et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 2005, 280:32618-32624.
70. Carlezon W.A., et al. Regulation of cocaine reward by CREB. Science 1998, 282:2272-2275.
71. Maiya R., et al. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1983-1988.
72. Gieryk A., et al. Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity. Psychopharmacology (Berl.) 2010, 208:291-300.
73. Schlussman S.D., et al. Regional mRNA expression of the endogenous opioid and dopaminergic systems in brains of C57Bl/6J and 129P3/J mice: strain and heroin effects. Pharmacol. Biochem. Behav. 2011, 100:8-16.
74. Levran O., et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 2008, 7:720-729.
75. Zhang H., et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol. Psychiatry 2008, 13:531-543.
76. Edenberg H.J., et al. A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum. Mol. Genet. 2008, 17:1783-1789.
77. Park S.W., et al. Retinoic acid-induced chromatin remodeling of mouse kappa opioid receptor gene. J. Neurosci. 2005, 25:3350-3357.
78. Park S.W., et al. Epigenetic regulation of kappa opioid receptor gene in neuronal differentiation. Neuroscience 2008, 151:1034-1041.
79. Taqi M.M., et al. Prodynorphin CpG-SNPs associated with alcohol dependence: elevated methylation in the brain of human alcoholics. Addict. Biol. 2011, 16:499-509.
80. Yuferov V., et al. Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs. Pharmacogenet. Genomics 2011, 21:185-196.
81. Ho M.K., et al. Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin. Pharmacol. Ther. 2010, 88:779-791.
82. Glick S.D., et al. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 1995, 681:147-152.
83. Negus S.S., et al. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 1997, 282:44-55.
84. Schenk S., et al. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl.) 1999, 144:339-346.
85. Walsh S.L., et al. Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 2001, 299:147-158.
86. Gold M.S., et al. Efficacy of clonidine in opiate withdrawal: a study of thirty patients. Drug Alcohol Depend. 1980, 6:201-208.
87. Bailey A., et al. Downregulation of kappa-opioid receptors in basolateral amygdala and septum of rats withdrawn for 14 days from an escalating dose 'binge' cocaine administration paradigm. Synapse 2007, 61:820-826.
88. Broadbear J.H., et al. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl.) 1994, 115:311-319.
89. Ko M.C., et al. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res. 2003, 982:38-44.
90. Melief E.J., et al. Duration of action of a broad range of selective kappa opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol. Pharmacol. 2011, 80:920-929.
91. Grimwood S., et al. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors. J. Pharmacol. Exp. Ther. 2011, 339:555-566.
92. Kreek M.J., et al. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 2002, 1:710-726.
93. Bart G., et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?. Neuropsychopharmacology 2005, 30:2254-2262.
94. Wentland M.P., et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg. Med. Chem. Lett. 2009, 19:2289-2294.
95. Zhang B., et al. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for kappa, mu, and delta opioid receptors. Bioorg. Med. Chem. 2011, 19:2808-2816.
96. Lovell K.M., et al. Synthesis of neoclerodane diterpenes and their pharmacological effects. Top. Curr. Chem. 2011, 299:141-185.
97. Wu H., et al. Structure of the human κ-opioid receptor in complex with JDTic. Nature 2012, 485:327-332.
98. Yuferov V., et al. Differential gene expression in the rat caudate putamen after 'binge' cocaine administration: advantage of triplicate microarray analysis. Synapse 2003, 48:157-169.
99. Bart G., et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 2004, 9:547-549.
100. Logrip M.L., et al. Stress modulation of drug self-administration: Implications for addiction comorbidity with post-traumatic stress disorder. Neuropharmacology 2012, 62:552-564.
101. Bidlack J.M., et al. Partial opioids. Medications for the treatment of pain and drug abuse. Ann. N. Y. Acad. Sci. 2000, 909:1-11.
102. Nielsen D.A., et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol. Psychiatry 2008, 13:417-428.
103. Crystal H.A., et al. A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict. Biol. 2012, 17:181-191.
104. Bart G., et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005, 30:417-422.
105. Proudnikov D., et al. Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. J. Infect. Dis. 2012, 205:1745-1756.
106. Zhang D., et al. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol. Psychiatry 2007, 61:1244-1251.
107. Manglik A., et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 2012, 485:400-404.